1. Home
  2. DFH vs CRVS Comparison

DFH vs CRVS Comparison

Compare DFH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dream Finders Homes Inc.

DFH

Dream Finders Homes Inc.

HOLD

Current Price

$15.22

Market Cap

1.2B

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

N/A

Current Price

$14.89

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DFH
CRVS
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
DFH
CRVS
Price
$15.22
$14.89
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$26.00
$30.17
AVG Volume (30 Days)
651.4K
822.2K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
0.37
N/A
Revenue
$4,322,848,000.00
N/A
Revenue This Year
$0.81
N/A
Revenue Next Year
$7.82
N/A
P/E Ratio
$40.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.20
$5.03
52 Week High
$31.10
$26.95

Technical Indicators

Market Signals
Indicator
DFH
CRVS
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
DFH
CRVS

About DFH Dream Finders Homes Inc.

Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: